Small Molecules
24 March 2013
ARIAD Announces That Iclusig (Ponatinib) Receives Positive CHMP Opinion for Approval in the European Union21 March 2013
FDA Approves Dotarem (gadoterate meglumine), first macrocyclic and ionic gadolinium-based contrast agent in USA21 March 2013
Orion Corporation Presented Promising Phase II Data for New Parkinson’s Disease Drug at AAN Annual Meeting21 March 2013
Orion Corporation Presented Promising Phase II Data for New Alzheimer’s Disease Drug at AAN Annual Meeting21 March 2013
Cytokinetics Announces Presentation of Phase IIA Clinical Trial Data of Tirasemtiv in Patients with Myasthenia Gravis21 March 2013
Intarcia Enrolls First Patients in “FREEDOM” Global Phase 3 Program for ITCA 650 in Type 2 Diabetes20 March 2013
BioLineRx Announces Results from Interim Analysis of Phase II/III CLARITY Trial of BL-1020 for Schizophrenia18 March 2013
Trimel Reports Positive CompleoTRT(TM) Phase III Results for Secondary Efficacy and Safety Endpoints18 March 2013
Virobay and LEO Pharma Initiate a Phase 1 Trial of VBY-891, a Compound Intended for Oral Treatment of PsoriasisNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports